The table below shows Aquestive Therapeutics, Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
Line item
FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
Operating cash flow
-$52.43M
-$35.76M
-$6.38M
-$9.82M
-$32.98M
-$45.46M
Capital expenditure
$562.00K
$159.00K
$995.00K
$1.02M
$913.00K
$517.00K
Investing cash flow
-$562.00K
-$159.00K
-$995.00K
-$2.52M
-$913.00K
-$517.00K
Dividends paid
-
-
-
-
AQST operating cash flow (10-K history)
Aquestive Therapeutics, Inc. reported operating cash flow of -$52.43M for fiscal year 2025. That is down 46.6% from -$35.76M in fiscal 2024. Over the 9 fiscal years shown, operating cash flow declined from $5.82M (FY 2017) to -$52.43M. Figures come from the company's audited annual reports as filed with the SEC.